URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
88.7%−2.8 pts over 5 years
Operating margin
-113.7%+960.4 pts over 5 years
Net margin
-139.8%+949.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +21.4% | +19.5% | +56.2% | – | |
| Gross profit | +19.4% | +19.7% | +55.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -11.9% | -92.9% | 268.6% | |
| Return on assets | – | -79.2% | -63.1% | |
| Current ratio | 7.03 | 5.39 | 4.01 | |
| Debt to equity | – | – | -1.16 | |
| Net debt to EBITDA | – | – | -0.09× | |
| Inventory turnover | – | – | 1.0× | |
| Capex to revenue | 4.0% | 10.3% | 0.3% | |
| Diluted shares | 2M | 22M | 48M |
Where the cash went
Fiscal 2021 to 2025, five years combined
UroGen Pharma generated $508.04M from operations and spent $1.78M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$508.04M
Used
$1.78M
Capital expenditure$1.78M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-139.8%
×Asset turnover0.45×
×Equity multiplier-4.25×
=Return on equity, FY2025268.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -139.8% | 0.45× | -4.25× | 268.6% |
| FY2024 | -140.4% | 0.39× | -6.27× | 342.8% |
| FY2023 | -123.6% | 0.53× | -2.03× | 132.3% |
| FY2022 | -170.6% | 0.50× | -3.15× | 271.2% |
| FY2021 | -230.7% | 0.40× | 2.31× | -211.6% |
| FY2020 | -1088.9% | 0.07× | 1.17× | -92.9% |
| FY2019 | -584144.4% | 0.00× | 1.13× | -77.8% |
| FY2018 | -6707.2% | 0.01× | 1.13× | -95.4% |
| FY2017 | -245.2% | 0.17× | 1.16× | -47.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$153.49M
- Cash generatingOperating cash flow above zero-$162.44M
- Return on assets improvedROA up on the prior year-71.2% → -53.7%
- Earnings backed by cashOperating cash flow above net income-$162.44M vs -$153.49M
- Less leverageLong-term debt to assets fell42.6% → 61.0%
- Better liquidityCurrent ratio rose6.01 → 4.01
- No dilutionShare count did not rise43M → 48M
- Gross margin improvedGross margin up on the prior year90.18% → 88.66%
- More efficientAsset turnover rose0.51 → 0.38